发明申请
- 专利标题: HEPATITIS B ANTIVIRAL AGENTS
-
申请号: US16114842申请日: 2018-08-28
-
公开(公告)号: US20190060258A1公开(公告)日: 2019-02-28
- 发明人: Yao-Ling Qiu , Xuri Gao , Jorden Kass , Hui Cao , Wei Li , Xiaowen Peng , Byung-Chul Suh , Yat Sun Or
- 申请人: ENANTA PHARMACEUTICALS, INC.
- 主分类号: A61K31/167
- IPC分类号: A61K31/167 ; A61K31/401 ; A61K31/4164 ; A61K31/34 ; A61K31/357 ; A61K31/4409 ; A61K31/426 ; A61K31/4015 ; A61K31/4439 ; A61K31/415 ; A61K31/421 ; A61K31/4192 ; A61K31/351 ; A61K31/397 ; A61K31/337 ; A61K31/47 ; A61K31/513 ; A61K31/7028 ; A61P31/20
摘要:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
公开/授权文献
- US10952978B2 Hepatitis B antiviral agents 公开/授权日:2021-03-23
信息查询